Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 54Dermatologic 19Other hematologic neoplasm 15Plasma cell 7Gastrointestinal 7Genitourinary 6Breast 5Thoracic 4Sarcoma 4Head & Neck 3Endocrine 3CNS 3Myeloid 2Gynecologic 2Tumor-Agnostic 1NET 1Classical hematology 1

Conditions

Carcinoma, Ovarian Epithelial 2Ovarian Neoplasms 1

Interventions

Paclitaxel 575Carboplatin 520Cisplatin 347Bevacizumab 252pembrolizumab 226Gemcitabine 157Topotecan 128liposomal doxorubicin 127Cyclophosphamide 126olaparib 120Taxes 113Radiotherapy 110Docetaxel 94Brachytherapy 89Doxorubicin 84Drug Therapy 80niraparib 75Nivolumab 71Magnetic Resonance Spectroscopy 71Specimen Handling 65fludarabine 56Biopsy 55Hyperthermic Intraperitoneal Chemotherapy 53Filgrastim 52Letrozole 50Oxaliplatin 48durvalumab 47Immunoglobulin G 47atezolizumab 46Platinum 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × romidepsin × Gynecologic × Clear all
NCT00085527 2013-09-05

FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer

University of Chicago

Phase 2 Withdrawn
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00091195 2013-03-19

Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
51 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡